I see another PI3K inhibitor being developed which can also cross the BBB. Planning to enter the clinic in 2024 in TNBC patients.
So miles behind, but may look to take market share in future (if PAX ever makes it to market).
https://globalcancertechnology.com/
I see another PI3K inhibitor being developed which can also...
Add to My Watchlist
What is My Watchlist?